samedan logo
 
 
spacer
home > pmps > spring 2017 > join the crowd
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Join the Crowd

PMPS: What can visitors expect to see at this year's PPMA Show?

Valerio Del Vecchio: Back at the NEC, Birmingham, on 26-28 September, the show provides insights into the latest processing and packaging machinery, technologies and materials. Presenting visitors with the chance to find inspiration, fresh ideas and solutions, it offers access to new suppliers and the opportunity to see machinery in action.

What new features will be launched this year?

Attendees will be able to discover the latest industry developments in the Learning Hub, which looks to deliver invaluable intuition from thought leaders. A full speaker programme will be announced soon, but one early confirmation is popular TED speaker and Chartered Engineer Peter Anderton, who is set to give his tworule approach to great leadership.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

FUJIFILM Irvine Scientific Begins Customer Qualification of European Manufacturing Facility

SANTA ANA, California, September 29, 2021: FUJIFILM Irvine Scientific, Inc., today announced that it completed construction and started the commissioning phase of its new manufacturing facility in Tilburg, the Netherlands. The commissioning milestone marks the beginning of validating the facility and equipment in anticipation of full operations starting in late 2021.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement